April 15 (Reuters) - CV Therapeutics Inc said it received $175 million from investment firm TPG-Axon Capital for rights to 50 percent of royalty on the company's heart-imaging agent, Lexiscan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results